HB-0036 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HB-0036’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HB-0036 overview

HB-0036 a bispecific antibody is under development for the treatment of solid tumors, non-small cell lung cancer, esophageal squamous cell carcinoma, melanoma, cervical cancer, head and neck squamous cell carcinomas, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma. It acts by targeting TIGIT and PD-L1. It is administered through intravenous route.

Huabo Biopharm (Shanghai) overview

Huabo Biopharm Co Ltd (Huabobio), a subsidiary of Zhejiang Huahai Pharmaceutical Co Ltd is a developer and marketer of therapies for the treatment of patients with tumors. The company develops drugs by using bi-functional protein technology platform, domain protein technology and antibody engineering technology. Its pipeline products include HB-001, HB-002T, HB-005, HB-008, HB-016, HB-017, HB-018, HOT-1020, and HOT-3020, among others. Huabobio’s antibody engineering technology and bi-functional protein technology platform supports in developing protein and antibody drugs with improved therapeutic efficacy. The company promotes tumor metastasis at late stage of tumor progression through inducing epithelial mesenchymal transition, inhibiting tumor immunity; and tumor angiogenesis through induction of angiogenic mediators such as vascular endothelial growth factor. Huabobio is headquartered in Shanghai, China.

For a complete picture of HB-0036’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.